BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38550394)

  • 1. Preclinical evaluation of protein synthesis inhibitor omacetaxine in pediatric brainstem gliomas.
    Chen Y; Khan A; Katsinas C; Michniewicz F; Goldberg J; Franshaw L; Tsoli M; Ziegler DS
    Neurooncol Adv; 2024; 6(1):vdae029. PubMed ID: 38550394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical evaluation of convection-enhanced delivery of liposomal doxorubicin to treat pediatric diffuse intrinsic pontine glioma and thalamic high-grade glioma.
    Sewing ACP; Lagerweij T; van Vuurden DG; Meel MH; Veringa SJE; Carcaboso AM; Gaillard PJ; Peter Vandertop W; Wesseling P; Noske D; Kaspers GJL; Hulleman E
    J Neurosurg Pediatr; 2017 May; 19(5):518-530. PubMed ID: 28291423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Doxorubicin-Loaded Gold Nanoarchitectures as a Therapeutic Strategy against Diffuse Intrinsic Pontine Glioma.
    Ung C; Tsoli M; Liu J; Cassano D; Pocoví-Martínez S; Upton DH; Ehteda A; Mansfeld FM; Failes TW; Farfalla A; Katsinas C; Kavallaris M; Arndt GM; Vittorio O; Cirillo G; Voliani V; Ziegler DS
    Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33805713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist.
    Xu C; Liu H; Pirozzi CJ; Chen LH; Greer PK; Diplas BH; Zhang L; Waitkus MS; He Y; Yan H
    Acta Neuropathol Commun; 2021 Nov; 9(1):178. PubMed ID: 34732238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microtubule-Targeting Combined with HDAC Inhibition Is a Novel Therapeutic Strategy for Diffuse Intrinsic Pontine Gliomas.
    Ehteda A; Khan A; Rajakumar G; Vanniasinghe AS; Gopalakrishnan A; Liu J; Tsoli M; Ziegler DS
    Mol Cancer Ther; 2023 Dec; 22(12):1413-1421. PubMed ID: 37683275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-tumor efficacy of anti-GD2 CAR NK-92 cells in diffuse intrinsic pontine gliomas.
    Zuo P; Li Y; He C; Wang T; Zheng X; Liu H; Wu Z; Zhang J; Liao X; Zhang L
    Front Immunol; 2023; 14():1145706. PubMed ID: 37251413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual targeting of mitochondrial function and mTOR pathway as a therapeutic strategy for diffuse intrinsic pontine glioma.
    Tsoli M; Liu J; Franshaw L; Shen H; Cheng C; Jung M; Joshi S; Ehteda A; Khan A; Montero-Carcabosso A; Dilda PJ; Hogg P; Ziegler DS
    Oncotarget; 2018 Jan; 9(7):7541-7556. PubMed ID: 29484131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical evaluation of dasatinib alone and in combination with cabozantinib for the treatment of diffuse intrinsic pontine glioma.
    Truffaux N; Philippe C; Paulsson J; Andreiuolo F; Guerrini-Rousseau L; Cornilleau G; Le Dret L; Richon C; Lacroix L; Puget S; Geoerger B; Vassal G; Östman A; Grill J
    Neuro Oncol; 2015 Jul; 17(7):953-64. PubMed ID: 25534822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MELK Inhibition in Diffuse Intrinsic Pontine Glioma.
    Meel MH; de Gooijer MC; Guillén Navarro M; Waranecki P; Breur M; Buil LCM; Wedekind LE; Twisk JWR; Koster J; Hashizume R; Raabe EH; Montero Carcaboso A; Bugiani M; van Tellingen O; van Vuurden DG; Kaspers GJL; Hulleman E
    Clin Cancer Res; 2018 Nov; 24(22):5645-5657. PubMed ID: 30061363
    [No Abstract]   [Full Text] [Related]  

  • 10. A high-throughput in vitro drug screen in a genetically engineered mouse model of diffuse intrinsic pontine glioma identifies BMS-754807 as a promising therapeutic agent.
    Halvorson KG; Barton KL; Schroeder K; Misuraca KL; Hoeman C; Chung A; Crabtree DM; Cordero FJ; Singh R; Spasojevic I; Berlow N; Pal R; Becher OJ
    PLoS One; 2015; 10(3):e0118926. PubMed ID: 25748921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent anti-tumor efficacy of palbociclib in treatment-naïve H3.3K27M-mutant diffuse intrinsic pontine glioma.
    Sun Y; Sun Y; Yan K; Li Z; Xu C; Geng Y; Pan C; Chen X; Zhang L; Xi Q
    EBioMedicine; 2019 May; 43():171-179. PubMed ID: 31060906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical analysis of MTOR complex 1/2 inhibition in diffuse intrinsic pontine glioma.
    Flannery PC; DeSisto JA; Amani V; Venkataraman S; Lemma RT; Prince EW; Donson A; Moroze EE; Hoffman L; Levy JMM; Foreman N; Vibhakar R; Green AL
    Oncol Rep; 2018 Feb; 39(2):455-464. PubMed ID: 29207163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation of diffuse intrinsic pontine glioma mouse models by brainstem-targeted in utero electroporation.
    Patel SK; Hartley RM; Wei X; Furnish R; Escobar-Riquelme F; Bear H; Choi K; Fuller C; Phoenix TN
    Neuro Oncol; 2020 Mar; 22(3):381-392. PubMed ID: 31638150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fimepinostat Impairs NF-κB and PI3K/AKT Signaling and Enhances Gemcitabine Efficacy in H3.3K27M-Diffuse Intrinsic Pontine Glioma.
    Wang D; Yan K; Yu H; Li H; Zhou W; Hong Y; Guo S; Wang Y; Xu C; Pan C; Tang Y; Liu N; Wu W; Zhang L; Xi Q
    Cancer Res; 2024 Feb; 84(4):598-615. PubMed ID: 38095539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of mutant PPM1D enhances DNA damage response and growth suppressive effects of ionizing radiation in diffuse intrinsic pontine glioma.
    Akamandisa MP; Nie K; Nahta R; Hambardzumyan D; Castellino RC
    Neuro Oncol; 2019 Jun; 21(6):786-799. PubMed ID: 30852603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Poly-ADP-Ribose Polymerase as a Therapeutic Target in Pediatric Diffuse Intrinsic Pontine Glioma and Pediatric High-Grade Astrocytoma.
    Chornenkyy Y; Agnihotri S; Yu M; Buczkowicz P; Rakopoulos P; Golbourn B; Garzia L; Siddaway R; Leung S; Rutka JT; Taylor MD; Dirks PB; Hawkins C
    Mol Cancer Ther; 2015 Nov; 14(11):2560-8. PubMed ID: 26351319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting of the alpha
    Cobb DA; de Rossi J; Liu L; An E; Lee DW
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35210306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune-stimulatory (TK/Flt3L) gene therapy opens the door to a promising new treatment strategy against brainstem gliomas.
    Faisal SM; Mendez FM; Nunez F; Castro MG; Lowenstein PR
    Oncotarget; 2020 Dec; 11(50):4607-4612. PubMed ID: 33400737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacologic inhibition of lysine-specific demethylase 1 as a therapeutic and immune-sensitization strategy in pediatric high-grade glioma.
    Bailey CP; Figueroa M; Gangadharan A; Yang Y; Romero MM; Kennis BA; Yadavilli S; Henry V; Collier T; Monje M; Lee DA; Wang L; Nazarian J; Gopalakrishnan V; Zaky W; Becher OJ; Chandra J
    Neuro Oncol; 2020 Sep; 22(9):1302-1314. PubMed ID: 32166329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined Therapy of AXL and HDAC Inhibition Reverses Mesenchymal Transition in Diffuse Intrinsic Pontine Glioma.
    Meel MH; de Gooijer MC; Metselaar DS; Sewing ACP; Zwaan K; Waranecki P; Breur M; Buil LCM; Lagerweij T; Wedekind LE; Twisk JWR; Koster J; Hashizume R; Raabe EH; Montero Carcaboso Á; Bugiani M; Phoenix TN; van Tellingen O; van Vuurden DG; Kaspers GJL; Hulleman E
    Clin Cancer Res; 2020 Jul; 26(13):3319-3332. PubMed ID: 32165429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.